Form 4: Veracyte CEO Marc Stapley Sells Shares Under 10b5-1 Plan

Veracyte's CEO, Marc Stapley, executed sales of common stock on March 4, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 4, 2025, Marc Stapley, the CEO of Veracyte, Inc., sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• A total of 52,697 shares were sold in multiple transactions at weighted average prices of $32.823, $33.9117, and $34.3685.
• Following these transactions, Stapley directly owns 268,035 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to stock sales by an insider under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on material non-public information. The use of a 10b5-1 plan provides a legal framework for insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sales do not appear to have any impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Veracyte, VCYT, Marc Stapley, SEC Form 4, Rule 10b5-1, Stock Sale, Insider Trading